These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6295190)

  • 1. Regression of myocardial hypertrophy and influence of adrenergic system.
    Sen S; Tarazi RC
    Am J Physiol; 1983 Jan; 244(1):H97-101. PubMed ID: 6295190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats.
    Nguyen T; El Salibi E; Rouleau JL
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):884-95. PubMed ID: 9869493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
    Zolk O; Flesch M; Schnabel P; Teisman AC; Pinto YM; van Gilst WH; Paul M; Böhm M
    Br J Pharmacol; 1998 Feb; 123(3):405-12. PubMed ID: 9504380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of cardiac hypertrophy. Experimental animal model.
    Sen S
    Am J Med; 1983 Sep; 75(3A):87-93. PubMed ID: 6137950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats.
    Pegram BL; Ishise S; Frohlich ED
    Cardiovasc Res; 1982 Jan; 16(1):40-6. PubMed ID: 6460557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular hypertrophy in spontaneously hypertensive rats.
    Sen S; Tarazi RC
    J Hypertens Suppl; 1986 Oct; 4(3):S123-6. PubMed ID: 2946822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment.
    Bing OH; Sen S; Conrad CH; Brooks WW
    Eur Heart J; 1984 Dec; 5 Suppl F():43-52. PubMed ID: 6241902
    [No Abstract]   [Full Text] [Related]  

  • 8. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.
    Donohue TJ; Dworkin LD; Ma J; Lango MN; Catanese VM
    J Investig Med; 1997 Dec; 45(9):584-91. PubMed ID: 9444886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats.
    Thandapilly SJ; Louis XL; Behbahani J; Movahed A; Yu L; Fandrich R; Zhang S; Kardami E; Anderson HD; Netticadan T
    Hypertens Res; 2013 Oct; 36(10):866-72. PubMed ID: 23784505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term hydralazine treatment on myocardial structure and expression of myosin isogenes in cardiac pressure overload in rats.
    Reddy DS; Singh M; Ganguly NK
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):261-71. PubMed ID: 8803958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of beta 1-adrenoceptors in hypertensive cardiac hypertrophy.
    Lindpaintner K; Sen S
    J Hypertens; 1987 Dec; 5(6):663-9. PubMed ID: 2828468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regression of left heart hypertrophy in arterial hypertension: principles, experimental and clinical findings].
    Klaus D
    Z Kardiol; 1985; 74 Suppl 7():153-69. PubMed ID: 2936016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats.
    Sen S; Tarazi RC; Bumpus FM
    Hypertension; 1980; 2(2):169-76. PubMed ID: 6445875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
    Ruskoaho H
    Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats.
    Tanabe A; Naruse M; Adachi C; Seki T; Yoshimoto T; Takagi S; Naruse K; Takano K
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S176-8. PubMed ID: 11078370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of left ventricular hypertrophy and control of hypertension in the spontaneously hypertensive rat (SHR): oxprenolol versus hydrochlorothiazide.
    Idikio H; Fernandez PG; Triggle CR; Kim BK
    Clin Invest Med; 1983; 6(1):43-8. PubMed ID: 6219850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of myocardial hypertrophy in prehypertensive spontaneously hypertensive rats: interaction between adrenergic and nitrosative pathways.
    Cabassi A; Dancelli S; Pattoneri P; Tirabassi G; Quartieri F; Moschini L; Cavazzini S; Maestri R; Lagrasta C; Graiani G; Corradi D; Parenti E; Tedeschi S; Cremaschi E; Coghi P; Vinci S; Fiaccadori E; Borghetti A
    J Hypertens; 2007 Aug; 25(8):1719-30. PubMed ID: 17620971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenergic activity and myocardial anatomy and function in essential hypertension.
    Muiesan G; Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1985 Dec; 3(4):S45-50. PubMed ID: 3007705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotection by beta-blockers: molecular and structural aspects in experimental hypertension.
    Pauletto P; Vescovo G; Scannapieco G; Pessina AC; Dal Palù C
    Drugs Exp Clin Res; 1990; 16(3):123-8. PubMed ID: 1974839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats.
    King RA; Smith RM; Krishnan R; Cleary EG
    J Hypertens; 1992 Sep; 10(9):919-28. PubMed ID: 1328373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.